Alkermes Plc (ALKS)
43.63
-0.55
(-1.24%)
USD |
NASDAQ |
Oct 23, 16:00
43.61
-0.02
(-0.05%)
After-Hours: 20:00
Alkermes Enterprise Value : 8.226B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 8.226B |
| October 22, 2026 | 8.318B |
| October 21, 2026 | 8.201B |
| October 20, 2026 | 8.306B |
| October 19, 2026 | 8.115B |
| October 16, 2026 | 7.822B |
| October 15, 2026 | 7.634B |
| October 14, 2026 | 7.463B |
| October 13, 2026 | 7.572B |
| October 12, 2026 | 7.661B |
| October 09, 2026 | 7.720B |
| October 08, 2026 | 7.636B |
| October 07, 2026 | 7.860B |
| October 06, 2026 | 7.894B |
| October 05, 2026 | 8.080B |
| October 02, 2026 | 7.911B |
| October 01, 2026 | 7.708B |
| September 30, 2026 | 7.705B |
| September 29, 2026 | 7.752B |
| September 28, 2026 | 7.643B |
| September 25, 2026 | 7.760B |
| September 24, 2026 | 7.750B |
| September 23, 2026 | 7.974B |
| September 22, 2026 | 8.169B |
| September 21, 2026 | 8.318B |
| Date | Value |
|---|---|
| September 18, 2026 | 8.186B |
| September 17, 2026 | 8.742B |
| September 16, 2026 | 8.635B |
| September 15, 2026 | 8.628B |
| September 14, 2026 | 8.594B |
| September 11, 2026 | 8.618B |
| September 10, 2026 | 8.641B |
| September 09, 2026 | 8.522B |
| September 08, 2026 | 8.537B |
| September 04, 2026 | 8.640B |
| September 03, 2026 | 8.770B |
| September 02, 2026 | 8.911B |
| September 01, 2026 | 8.824B |
| August 31, 2026 | 8.789B |
| August 28, 2026 | 8.859B |
| August 27, 2026 | 9.109B |
| August 26, 2026 | 9.152B |
| August 25, 2026 | 9.161B |
| August 24, 2026 | 9.104B |
| August 21, 2026 | 9.013B |
| August 20, 2026 | 8.961B |
| August 19, 2026 | 9.323B |
| August 18, 2026 | 9.206B |
| August 17, 2026 | 9.268B |
| August 14, 2026 | 9.136B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amarin Corp. Plc | -61.98M |
| Prothena Corp. Plc | 143.10M |
| Incyte Corp. | 18.76B |
| Cue Biopharma, Inc. | 89.00M |
| ADC Therapeutics SA | 81.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.501M |
| Revenue (Quarterly) | 496.01M |
| Total Expenses (Quarterly) | 495.51M |
| EPS Diluted (Quarterly) | 0.0029 |
| Gross Profit Margin (Quarterly) | 75.30% |
| Profit Margin (Quarterly) | 0.10% |
| Earnings Yield | 0.88% |
| Operating Earnings Yield | 1.94% |
| Normalized Earnings Yield | 1.127 |